GlassScriptPhysician profile
Susmitha Dhanyamraju
NPI 1346479946
$7,396.41
in general payments reported to CMS, 2019-2025
19 companies · $587 in 2025
The $587 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $385 · 2022: $5,315 · 2023: $340 · 2024: $222 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $5,203.91 | 2022-2023 | |
| Mallinckrodt Enterprises LLC | $346.06 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $261.05 | 2019-2025 | Jynarque |
| Nxstage Medical, INC. | $244.37 | 2023-2025 | Nxstage System One, Pureflow Sl |
| Amgen INC. | $235.91 | 2019-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $220.24 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $153.07 | 2025 | Empaveli |
| Opko Pharmaceuticals, LLC | $135.64 | 2019-2020 | |
| Ardelyx, INC. | $125.00 | 2024 | Xphozah 30 Mg |
| Calliditas Therapeutics US INC. | $118.76 | 2023-2024 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $109.32 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.48 | 2025 | |
| Akebia Therapeutics INC | $44.23 | 2019-2025 | Vafseo |
| Ultragenyx Pharmaceutical INC. | $37.47 | 2020 | |
| Alexion Pharmaceuticals, INC. | $31.96 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $24.96 | 2023 | Renal - Pd |
| Horizon Therapeutics Plc | $19.93 | 2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $18.20 | 2019 | |
| Avion Pharmaceuticals | $12.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susmitha Dhanyamraju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.